BioLineRx Ltd.
BioLineRx Ltd. (BLRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blrx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioLineRx Ltd. (BLRX) measures how much investors pay for each dollar of the company's trailing earnings. BLRX's current PE ratio of N/A is calculated by dividing its stock price of $3.25 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioLineRx Ltd.You BLRX | $14M | N/A | — | -$0.00 |
 Adaptimmune Therapeutics plc ADAP | $75M | N/A | — | -$0.28 |
 Aditxt, Inc. ADTX | $0M | N/A | — | -$1116.70 |
 Ainos, Inc. AIMD | $9M | N/A | — | -$3.46 |
 Adlai Nortye Ltd. ANL | $543M | N/A | — | -$3.33 |
 Apollomics, Inc. APLM | $15M | N/A | — | -$7.57 |
 GeoVax Labs, Inc. GOVX | $1M | N/A | — | -$22.40 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.29 | — | |
2024-12-31 FY2024 | — | $-0.12 | — | |
2023-12-31 FY2023 | — | $-0.94 | — | |
2022-12-31 FY2022 | — | $-0.48 | — | |
2021-12-31 FY2021 | — | $-0.61 | — | |
2020-12-31 FY2020 | — | $-1.78 | — | |
2019-12-31 FY2019 | — | $-2.61 | — | |
2018-12-31 FY2018 | — | $-3.17 | — | |
2017-12-31 FY2017 | — | $-4.06 | — | |
2016-12-31 FY2016 | — | $-4.23 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioLineRx Ltd. (BLRX) measures how much investors pay for each dollar of the company's trailing earnings. BLRX's current PE ratio of N/A is calculated by dividing its stock price of $3.25 by its TTM earnings per share of -$0.00.
Frequently asked questions
BLRX pe ratio · 6 questionsBLRX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.25 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via BLRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioLineRx Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08